Intra-Cellular Therapies (ITCI) 10-K2019 FY Annual report

Filed: 2 Mar 20, 8:02am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accommodate, adrenergic, adversarial, allegedly, alpha, alter, ameliorate, amendedi, approvedthe, April, assert, asserted, attach, attempt, Book, BR, CAPLYTA, CAPLYTATM, cellular, compulsory, contributor, council, Crystal, crystalline, dedicated, Delinquent, deploy, detention, embedded, emergent, evenly, exhaustion, explicit, foregoing, formatted, harmonization, histaminergic, IL, immune, implicit, impossible, inclusion, inflammation, inflammatory, Inline, intangible, invoiced, Leerink, lessee, lifetime, mandatory, merit, methodology, misuse, muscarinic, NaN, narrowly, negligence, network, Note, outweigh, owner, Page, path, pooled, postsynaptic, proliferation, provoke, prudent, readability, recordkeeping, reestablish, refine, revocation, Rule, salt, seizure, sNDA, solid, strict, sued, SVB, text, tosylate, underwritten, unlimited, unpaid, unsuitable, vestedduring, vivarium, voluntary, waiver, wereapproximately, wholesale

Removed: acetylcholinesterase, acutely, adequacy, AE, akathisia, Allergan, American, ANCOVA, antagonism, approximating, ascending, ASD, ASUNo, avoidance, block, blockade, Bonferroni, borrowed, build, Calgary, capability, categorized, ceased, centrally, Certified, characteristic, children, collaborate, collateral, combined, comprise, confirm, confirmed, confounding, contrast, corporation, covariance, daytime, deep, developmentally, diagnosed, differentiating, disproportionately, dopaminergic, DPPM, dual, employing, entering, evidenced, exacerbate, examination, exchanged, exhibited, existence, expectation, exploring, facilitate, Fanapt, fatal, feasibility, formally, functional, glutamate, host, hyperprolactinemia, Impression, incorporate, induced, inhibition, insulin, integrate, interfered, internally, interpersonal, introduced, Involuntary, ITT, jointly, latency, leading, lender, levodopa, LIBOR, LOCF, Lundbeck, mechanism, mediate, mesolimbic, missing, modulator, morning, motoric, narrower, neuropharmacological, nighttime, Notably, observation, occupancy, older, Otsuka, PET, pharmacology, phosphorylation, pioneering, played, point, polysomnography, poorer, posttraumatic, potent, powered, premarket, prematurely, procedure, proceeded, profound, prolactin, promising, psychopathology, psychosocial, Reg, regional, relief, repaid, Repeated, reposition, reversal, robust, role, schizoaffective, secured, selectivity, separated, serotonergic, signal, simple, SMI, solve, spend, stabilization, stabilizer, stereotyped, stimulate, striatal, strongly, subgroup, subscale, subset, sue, suffered, suggested, Sunovion, supportive, surviving, symptom, tension, terminating, thisForm, thought, today, training, trajectory, unblinding, understand, unnecessarily, unusually, UpdateNo, visit, VRAYLAR, waking, washout, wave, weekly, Whistleblower, worse

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ITCI transcripts

ITCI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statement (FormS-3No. 333-235817) of Intra-Cellular Therapies, Inc.,

(2) Registration Statement (FormS-3No. 333-233537) of Intra-Cellular Therapies, Inc.,

(3) Registration Statement (FormS-8No. 333-225799) pertaining to the Intra-Cellular Therapies, Inc. 2018 Equity Incentive Plan of Intra-Cellular Therapies, Inc.,

(4) Registration Statement (FormS-8No. 333-205070) pertaining to the Intra-Cellular Therapies, Inc. Amended and Restated 2013 Equity Incentive Plan of Intra-Cellular Therapies, Inc.,

(5) Registration Statement (Post-Effective Amendment No. 3 to FormS-1 on FormS-3No. 333-191238) of Intra-Cellular Therapies, Inc., and

(6) Registration Statement (FormS-8No. 333-193310) pertaining to the ITI, Inc. 2003 Equity Incentive Plan, as amended, and the Intra-Cellular Therapies, Inc. 2013 Equity Incentive Plan of Intra-Cellular Therapies, Inc.;

of our reports dated March 2, 2020, with respect to the consolidated financial statements of Intra-Cellular Therapies, Inc. and the effectiveness of internal control over financial reporting of Intra-Cellular Therapies, Inc. included in this Annual Report (Form10-K) of Intra-Cellular Therapies, Inc. for the year ended December 31, 2019.

/s/ Ernst & Young LLP

Baltimore, Maryland

March 2, 2020